The Council for Medical Schemes (CMS), South Africa’s medical scheme industry regulator, has declined a request from the Autoimmune Alliance of SA (AASA) to issue clear guidance on funding expensive biologic treatments for autoimmune diseases. CMS emphasized that each case must be assessed on its own merits, rejecting a blanket directive for funding. The AASA has been actively lobbying the…